Kratikal Tech Investor Presentation: Key Takeaways
H1 FY27 revenue ₹22.32 Cr (+65.2%), EBITDA ₹4.09 Cr (18.3% margin), PAT ₹2.80 Cr (+129.5%). Strategy: scale overseas and move to product-led revenue.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
H1 FY27 revenue ₹22.32 Cr (+65.2%), EBITDA ₹4.09 Cr (18.3% margin), PAT ₹2.80 Cr (+129.5%). Strategy: scale overseas and move to product-led revenue.
Kratikal Tech's H1 FY27 revenue rose 65% to ₹22.32 Cr; PAT rose 130% to ₹2.80 Cr. Order book stood at ₹42.6 Cr.
Kratikal Tech reported no deviation in IPO fund use for the half year to September 30, 2026. Rs 4.25 crore of Rs 39.69 crore was utilised.
Kratikal Tech Ltd reported revenue from operations of ₹22.3 Cr (+65.2% YoY) and net profit of ₹2.8 Cr (+133.3% YoY) for H1 FY27.
Kratikal Tech will hold a board meeting on 05 Nov 2026 to consider half-year unaudited results. Trading window stays closed until 48 hours after declaration.
Kratikal Tech Ltd has filed its quarterly shareholding pattern as per SEBI regulations. This is a periodic compliance disclosure with no material event impact.
Kratikal Tech Ltd incorporated a wholly-owned subsidiary, Kratikal AI Inc., in Delaware, USA, as an SPV for cybersecurity operations with a USD 10,000 investment.
Kratikal Tech Limited has appointed GoIndia Advisors LLP to provide investor relations management services, effective October 08, 2026, to strengthen its investor engagement framework.
Kratikal Tech Ltd announced the grant of 17,996 employee stock options to eligible employees under its 2019 ESOP plan.
Kratikal Tech Limited has appointed Mittal V Kothari & Associates as Secretarial Auditor and MSMK & Co. as Internal Auditor, each for a 12-month term.
Kratikal Tech's board approved incorporating a wholly owned US subsidiary for cybersecurity and information security services. The Delaware-based entity is subject to regulatory approval.